From the November 7 2022 PR: November 22, 2022 8:
Post# of 154603
(Total Views: 590)
Posted On: 01/27/2025 10:51:57 PM
From the November 7 2022 PR:
November 22, 2022 8:30am EST
VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it will host a virtual R&D Update on Wednesday, December 7, 2022, beginning at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time.
During this event, Company management and members of its Scientific Advisory Board will provide an overview and update on the Company's R&D and clinical development strategy and activities.
CytoDyn's R&D Update will include the following:
Cyrus Arman, Ph.D., President, will provide an overview of the Company's current and future R&D and clinical development strategy and activities.
Mazen Noureddin, M.D., M.H.Sc., the current Director of the Houston Liver Institute and former founding Director of the Fatty Liver Program at Cedars-Sinai Medical Center. He has conducted over 40 investigational clinical studies and published over 180 papers on non-alcoholic steatohepatitis (NASH). He will present the potential role of leronlimab in treating NASH and non-alcoholic fatty liver disease.
November 22, 2022 8:30am EST
VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"
, a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it will host a virtual R&D Update on Wednesday, December 7, 2022, beginning at 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time. During this event, Company management and members of its Scientific Advisory Board will provide an overview and update on the Company's R&D and clinical development strategy and activities.
CytoDyn's R&D Update will include the following:
Cyrus Arman, Ph.D., President, will provide an overview of the Company's current and future R&D and clinical development strategy and activities.
Mazen Noureddin, M.D., M.H.Sc., the current Director of the Houston Liver Institute and former founding Director of the Fatty Liver Program at Cedars-Sinai Medical Center. He has conducted over 40 investigational clinical studies and published over 180 papers on non-alcoholic steatohepatitis (NASH). He will present the potential role of leronlimab in treating NASH and non-alcoholic fatty liver disease.
(5)
(0)